India, March 27 -- A University of South Carolina-licensed startup that has developed an intranasal drug delivery system for brain tumours marked a historic day as it listed for the first time on Nasdaq. The USC Stevens Center for Innovation and the startup, NeOnc Technologies, celebrated this milestone by ringing the opening bell on March 26.

Alongside this achievement, NeOnc announced a strategic partnership with CBCC Global Research, a premier full-service clinical research organisation (CRO), to expand clinical trials across 30 FDA-compliant sites in India, facilitating the advancement of its neuro-oncology treatment.

NeOnc is based on intellectual property developed by neurosurgeon and NeOnc founder Thomas Chen of Keck Medicine of ...